/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Kiniksa Pharmaceuticals International Plc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$40.61 0.013(1.3%) KNSA at 04 Dec 2025 04:36 PM Drug Manufacturers - Specialty & Generic
Lowest Today 39.62
Highest Today 40.68
Today’s Open 40.34
Prev. Close 40.07
52 Week High 42.98
52 Week Low 17.82
Day’s Range: Low 39.62 High 40.68
52-Week Range: Low 17.82 High 42.98
1 day return -
1 Week return -5.04
1 month return +5.25
3 month return +14.2
6 month return +40.41
1 year return +91.79
3 year return +158.37
5 year return +128.14
10 year return -

Institutional Holdings

Rubric Capital Management LP 5.28

Vanguard Group Inc 4.23

Baker Bros Advisors LP 3.81

TANG CAPITAL MANAGEMENT LLC 3.14

Fairmount Funds Management LLC 2.39

Vanguard Total Stock Mkt Idx Inv 1.61

BRAIDWELL LP 1.49

Morgan Stanley - Brokerage Accounts 1.44

Millennium Management LLC 1.38

Pictet Asset Manangement SA 1.33

Vanguard Small Cap Index 1.25

Qube Research & Technologies 1.20

Point72 Asset Management, L.P. 1.15

FMR Inc 1.09

D. E. Shaw & Co LP 1.07

Arrowstreet Capital Limited Partnership 0.99

BlackRock Inc 0.95

Cubist Systematic Strategies, LLC 0.89

Dimensional Fund Advisors, Inc. 0.87

Driehaus Capital Management LLC 0.87

Rice Hall James & Associates, LLC 0.86

Connor Clark & Lunn Inv Mgmt Ltd 0.84

Pictet-Biotech P USD 0.73

Vanguard Small Cap Growth Index Inv 0.71

Fidelity Small Cap Growth 0.66

Pictet-Global Megatrend Sel I USD 0.56

Oberweis Micro-Cap 0.41

Oberweis Micro-Cap Growth 0.41

Heptagon Driehaus US Micro Cap Eq C$ Acc 0.36

Fidelity Small Cap Growth K6 0.30

Xtrackers MSCI World Swap ETF 1C 0.23

Xtrackers S&P 500 Swap ETF 1C 0.19

Peregrine Capital Mgt Sm-Cap Growth 0.18

Allspring Small Company Gr 0.17

Allspring Small Company Growth A 0.17

Vanguard Strategic Equity Inv 0.16

DFA US Small Cap I 0.16

Scout Small Cap Equity 0.15

Vanguard Explorer Inv 0.15

Driehaus Micro Cap Growth USD 0.14

Market Status

Strong Buy: 4

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 3037.14 M

PB Ratio 5.7946

PE Ratio 89.0445

Enterprise Value 2759.94 M

Total Assets 580.55 M

Volume 231835

Company Financials

Annual Revenue FY24:423239000 423.2M, FY23:248748000 248.7M, FY22:220180000 220.2M, FY21:38544000 38.5M, FY20:0 0.0M

Annual Profit FY24:423239000 423.2M, FY23:195179000 195.2M, FY22:173214000 173.2M, FY21:29444000 29.4M, FY20:null 0.0M

Annual Net worth FY24:-43193000 -43.2M, FY23:-6692000 -6.7M, FY22:183363000 183.4M, FY21:-157924000 -157.9M, FY20:-161381000 -161.4M

Quarterly Revenue Q3/2025:180855000 180.9M, Q2/2025:156797000 156.8M, Q1/2025:137785000 137.8M, Q3/2024:112214000 112.2M, Q2/2024:108631000 108.6M

Quarterly Profit Q3/2025:97264000 97.3M, Q2/2025:85763000 85.8M, Q1/2025:76127000 76.1M, Q3/2024:62798000 62.8M, Q2/2024:66176000 66.2M

Quarterly Net worth Q3/2025:18435000 18.4M, Q2/2025:17832000 17.8M, Q1/2025:8539000 8.5M, Q3/2024:-12693000 -12.7M, Q2/2024:-3908000 -3.9M

Fund house & investment objective

Company Information Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.

Organisation Drug Manufacturers - Specialty & Generic

Employees 315

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Sanj K. Patel

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow